Apogee Therapeutics to Participate in Upcoming June Investor Conferences
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotech company focused on developing biologics for atopic dermatitis, COPD, asthma, and other inflammatory and immunology conditions, announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotech company focused on developing biologics for atopic dermatitis, COPD, asthma, and other inflammatory and immunology conditions, announced its participation in two upcoming investor conferences. The Jefferies Global Healthcare Conference will take place on June 6, 2024, at 8:30 a.m. ET, followed by the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 11:20 a.m. ET. Live and archived webcasts of these events will be accessible through the company's website.
Positive
- Participation in high-profile investor conferences may increase visibility and attract potential investors.
- Opportunities to present at Jefferies and Goldman Sachs conferences signal industry recognition and credibility.
Negative
- The press release lacks specific updates on financial performance or clinical trial progress, which may leave investors seeking more substantive information.
- No new product developments or partnerships were announced, which could mean immediate business growth.
Details
News Market Reaction – APGE
The recorded move for APGE in the trading session of this news was -3.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that members of management will participate at the following upcoming investor conferences:
Jefferies Global Healthcare Conference
Date: Thursday, June 6, 2024
Time: 8:30 a.m. ET
Goldman Sachs 45th Annual Global Healthcare Conference
Date: Monday, June 10, 2024
Time: 11:20 a.m. ET
A live and archived webcast of the fireside chat and presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.